Fig. 2

Ouabain preferentially targets primitive AML cells. A Profiles of different AML subpopulations, including CD34⁺CD38⁻ LSCs, CD34⁺CD38⁺ LPCs, CD34⁻CD38⁺ pre-LBs, and CD34⁻CD38⁻ LBs in human AML-derived KG-1, HL-60, and PL-21 cells, by flow cytometry. B Human AML-derived Kasumi-3 (M0) cells exhibited a similar profile of AML subpopulations as KG-1 cells (left) and dose–response curves upon ouabain treatment (0 − 300 nM) for 48 h (right). C Clonogenic assay in KG-1 (left) and HL-60 (right) with or without ouabain at the indicated concentrations after 14 days of culture. (upper) Number of leukemic colonies was plotted. Data are mean ± SD (n = 3). ^***P < 0.001 versus nontreated control; two-sided Student’s t test. (lower) Representative micrographs are shown. Scale bar = 500 μm